Table 1 Analysis of IRX2 mRNA expression in primary breast tumors. IRX2 expression was determined in one large published expression data set [29] and correlated to the indicated clinico-pathological parameters
From: Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells
IRX2 low | IRX2 high | P-value | ||||
|---|---|---|---|---|---|---|
n | % | n | % | |||
All patients | 998 | 50.1 | 994 | 49.9 % | ||
Histology | <0.001 | |||||
Ductal | 809 | 82.7 | 744 | 76.5 | ||
Lobular | 47 | 4.8 | 101 | 10.4 | ||
Ductolobular | 42 | 4.3 | 48 | 4.9 | ||
Others | 69 | 7.1 | 76 | 7.8 | ||
Tumor stage | 0.004 | |||||
1 | 174 | 31.8 | 198 | 39.4 | ||
2 | 308 | 56.2 | 271 | 53.9 | ||
3 + 4 | 66 | 12.1 | 34 | 6.8 | ||
Grade | <0.001 | |||||
1 | 59 | 6.2 | 111 | 11.7 | ||
2 | 352 | 36.9 | 423 | 44.7 | ||
3 | 544 | 57.0 | 413 | 43.6 | ||
Lymph node status | 0.044 | |||||
N0 | 503 | 50.4 | 546 | 54.9 | ||
N+ | 495 | 49.6 | 448 | 45.1 | ||
Tumor size | ||||||
<2 cm | 407 | 43.3 | 499 | 45.8 | 0.050 | |
>2 cm | 578 | 58.7 | 532 | 54.2 | ||
ER expression | 0.001 | |||||
Negative | 268 | 26.9 | 206 | 20.7 | ||
Positive | 730 | 73.1 | 788 | 79.3 | ||
PR expression | <0.001 | |||||
Negative | 540 | 54.1 | 403 | 40.5 | ||
Positive | 458 | 45.9 | 591 | 59.5 | ||
HER2 expression | 0.735 | |||||
Negative | 876 | 87.8 | 867 | 87.2 | ||
Positive | 122 | 12.2 | 127 | 12.8 | ||
Subtype | <0.001 | |||||
Basal | 206 | 20.7 | 125 | 12.6 | ||
HER2 | 121 | 12.2 | 119 | 12.0 | ||
LumA | 303 | 30.5 | 418 | 42.2 | ||
LumB | 292 | 29.3 | 200 | 20.2 | ||
P53 mutation status | 0.454 | |||||
Mutant | 56 | 12.9 | 43 | 11.1 | ||
wt | 378 | 87.1 | 343 | 88.9 | ||